Cargando…

In search of the ideal basal insulin: Does the new‐generation ultra‐long‐acting insulin, degludec, provide the answer?

Detalles Bibliográficos
Autores principales:	Hui, Elaine, Lam, Karen S L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley-Blackwell 2013
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019285/ https://www.ncbi.nlm.nih.gov/pubmed/24843628 http://dx.doi.org/10.1111/j.2040-1124.2012.00243.x

Ejemplares similares

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang, Fei, et al.
Publicado: (2012)

Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart
por: Havelund, Svend, et al.
Publicado: (2015)

Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine
por: Birkeland, Kåre I., et al.
Publicado: (2011)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with a Conventional Premixed Insulin or Basal Insulin: A Meta-Analysis
por: Moon, Shinje, et al.
Publicado: (2021)

Cardiovascular safety of long‐acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
por: Chang, Chia‐Hsuin, et al.
Publicado: (2017)

Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review
por: Woo, Vincent, et al.
Publicado: (2020)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Auxiliendo, Primum Non Nocere: A Preliminary View of the DEVOTE Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Type 2 Diabetes
por: Kalra, Sanjay
Publicado: (2017)

Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes
por: Jang, Han Na, et al.
Publicado: (2019)

Insulin degludec does not increase antibody formation versus insulin glargine: an evaluation of phase IIIa trials
por: Vora, J., et al.
Publicado: (2016)

Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose‐lowering effects
por: Haahr, Hanne, et al.
Publicado: (2016)

Switching Patients with Type 1 Diabetes to Insulin Degludec from Other Basal Insulins: Real-World Data of Effectiveness and Safety
por: Ponzani, Paola, et al.
Publicado: (2019)

Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function
por: Hartmann, Thorsten, et al.
Publicado: (2016)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
por: Tosaka, Yuka, et al.
Publicado: (2015)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
por: Kawaguchi, Yuji, et al.
Publicado: (2019)

Commentary to “Differential Effect of Hypoalbuminemia on Hypoglycemia on Type 2 Diabetes Patients Treated with Insulin Glargine 300 U/ml and Insulin Degludec” by Kawaguchi et al. Diabetes Therapy 2019
por: Pieber, Thomas R., et al.
Publicado: (2020)

Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study
por: Fadini, Gian Paolo, et al.
Publicado: (2019)

Real-world efficacy and safety of insulin degludec with mealtime rapid-acting insulin in type 1 diabetes in Indian pediatric population
por: Kochar, Inderpal Singh, et al.
Publicado: (2018)

Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control
por: Tentolouris, Nikolaos, et al.
Publicado: (2019)

Final Answer: Ghrelin Can Suppress Insulin Secretion in Humans, but Is It Clinically Relevant?
por: Meyer, Christian
Publicado: (2010)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
por: Pei, Yu, et al.
Publicado: (2021)

Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100
por: Alexopoulos, Anastasia‐Stefania, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_oh5j5l94qijjgi00rb8f6at12p